Multi-target repetitive transcranial magnetic stimulation (RTMS) treatment for major depressive disorder (MDD) and comorbid pain

Active Grant Awarded Last action

Award ID
K01MH123887
Recipient
Awarding agency
Obligated
$914,435

Award facts

Assistance listing
93.24X Mental Health Research - Other Research
Completion date 83% complete
Originally
Place of performance
Los Angeles, CA 90095, USA

Award details come from USAspending.gov.

Description

Abstract
Major depressive disorder (MDD) and fibromyalgia (FM) are highly comorbid, disabling and resistant to treatment. More than half of MDD patients present with pain symptoms, and the comorbidity is associated with reduced quality of life, poor pharmacological treatment outcomes, and opioid use disorders. New approaches to help comorbid patients are urgently needed. Repetitive transcranial magnetic stimulation (RTMS) treatment may ameliorate both pain and mood symptoms, possibly through modulation of shared underlying pathophysiological brain networks. Preliminary data indicate RTMS applied to the left dorsolateral prefrontal cortex (LDLPFC) significantly improved both depressive and moderate pain symptoms but failed to improve more severe comorbid pain. In this application, we propose to test the efficacy of a multi-target RTMS protocol that may be more successful in treating both mood and pain symptoms in comorbid MDD/FM. This includes two complementary objectives: 1) to test the effects of a novel RTMS protocol for comorbid MDD and FM, and 2) to provide critical additional training to the candidate that will facilitate her transition into independence as a researcher specializing in the comorbidity of mood disorders with chronic pain and their treatment with RTMS. This will be achieved through a randomized, sham-controlled study with two experimental conditions: a) active RTMS to LDLPFC (established target for MDD) and sham RTMS to the primary motor cortex (M1, established pain target); and B) active RTMS to both, LDLPFC and M1. We anticipate that multi-site RTMS will be more efficacious to treat both MDD and FM symptoms than the single site RTMS protocol. Additionally, we will determine the differences and similarities of neural signatures of MDD and FM and how these interact in the comorbid condition using machine learning techniques. The K01 project will take place at ucla with the mentoring support from the director of the neuromodulation division, two CO-mentors and four other collaborators with expertise in RTMS, depression, chronic pain, multimodal imaging, and machine learning analysis. This approach will achieve the project's specific aims to: 1. Evaluate the effect of multi-site VS. Single site RTMS on clinical symptoms; 2. Determine the interaction of networks affected in MDD and chronic pain and how they are modulated by RTMS; and 3. Examine the interaction between analgesic and antidepressant effects of RTMS. If these aims are achieved, the short-term outcome of this project will help determine the efficacy of multi-site RTMS for comorbid MDD and FM, identify the overlap of the neural signature of MDD and FM and how IT is modulated by RTMS, and characterize the relationship between RTMS-induced antidepressant and analgesic effects. In the long-term, current RTMS procedures may be significantly improved for the treatment of MDD with comorbid chronic pain.

Transactions

Action Obligated Date
Amendment $182,887
Amendment $182,887
Amendment $0
Amendment $182,887
Amendment $182,887
Original award $182,887

Quick answers

Who received award K01MH123887?

K01MH123887 was awarded to University Of California, LOS Angeles by National Institute of Mental Health (National Institutes of Health) on April 4, 2022.

How much is award K01MH123887 worth?

$914,435 has been obligated on K01MH123887.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award